Companies/Indivior Pharmaceuticals Inc

Company profile

Indivior Pharmaceuticals Inc

NASDAQ: INDV · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ North Chesterfield, VACIK 0001625297Reports USD

#138 of 1,394 Healthcare companies by revenue48th-percentile growth

EA Score

67B

FH 76DQ 51GM 64SS 77

v0.1 · 65/100 weight · provisional

↑ filing timeliness, return on assets · ↓ disclosure history, balance-sheet leverage

Methodology →

Revenue TTM

$1.3B

Rev growth YoY (TTM)

+10.2%

Net income (FY)

$210.0M

Employees

1,030

Market cap

$5.0B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.2B$1.2B2025

Net income$210.0M$210.0M2025

Operating income$262.0M$262.0M2025

Total assets$1.2B$1.2B2025

Liabilities$1.3B$1.3B2025

Equity-$98.0M-$98.0M2025

Revenue trend

FY2024 – FY2025 · USD

$901.0M

FY24

$1.1B

FY24

$1.2B

FY24

$1.2B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Reportable100%

By geography

Not disclosed.

The read

Indivior Pharmaceuticals Inc booked $1.2B in FY2025 revenue, growing 4.3% year over year — about the middle of the pack among Healthcare companies we track, at a 16.9% net margin.

Peers · Healthcare

10x Genomics, Inc.67B Alignment Healthcare, Inc.71B Definium Therapeutics, Inc.——Sotera Health Company70B

Key facts

CEOJoseph J. Ciaffoni

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersNorth Chesterfield, VA

ExchangeNASDAQ: INDV

Employees1,030

IPO date2014-12-29

Latest filings

8-K2026-05-15 8-K2026-05-04 10-Q2026-04-30 8-K2026-04-30 DEF 14A2026-03-27 8-K2026-03-17 8-K2026-03-13 8-K2026-03-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.